

Correction to: Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors

Nicki Niemann¹ · Joseph Jankovic¹

Published online: 10 March 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: Drugs
<https://doi.org/10.1007/s40265-018-0874-x>

Figure 1

The dose (mg/day) for Clonazepam which reads:
80–240

Should read:
0.25–4

Figure 1

The dose (mg/day) for *Gingko biloba* which reads:
0.25–4**

Should read:
80–400

Figure 1

The legend, which reads

Management of tardive dyskinesia. *DRBA* dopamine receptor-blocking agent, *GPI* globus pallidus interna, *TD* tardive dyskinesia, *VMAT2* vesicular monoamine transporter 2. *Similar side effects but may be better tolerated than tetrabenazine. **240 mg/day used in randomized controlled trial

Should read:

Management of tardive dyskinesia. *DRBA* dopamine receptor-blocking agent, *GPI* globus pallidus interna, *TD* tardive dyskinesia. *Deutetrabenazine and valbenazine may be better tolerated than tetrabenazine

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40265-018-0874-x>.

✉ Joseph Jankovic
josephj@bcm.edu;
<http://www.jankovic.org>

¹ Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, TX 77030, USA